{"id":"folfoxiri-bevacizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFOXIRI combines three chemotherapy agents (5-fluorouracil, oxaliplatin, and irinotecan) that work through different mechanisms to damage cancer cell DNA and prevent replication. Bevacizumab is a monoclonal antibody that binds to VEGF, preventing tumor blood vessel formation and starving tumors of nutrients. Together, they provide dual anti-cancer activity through cytotoxic chemotherapy and anti-angiogenic mechanisms.","oneSentence":"FOLFOXIRI is a combination chemotherapy regimen that inhibits DNA synthesis and cell division, while bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor (VEGF).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:14.459Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT06951503","phase":"PHASE3","title":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-05-27","conditions":"Colorectal Adenocarcinoma","enrollment":560},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT07229846","phase":"PHASE2","title":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation","status":"NOT_YET_RECRUITING","sponsor":"Yanqiao Zhang","startDate":"2026-02","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT06733038","phase":"PHASE3","title":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-11-15","conditions":"Colorectal Cancer","enrollment":238},{"nctId":"NCT07070713","phase":"PHASE2","title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-07-30","conditions":"Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy","enrollment":44},{"nctId":"NCT05727163","phase":"PHASE2","title":"FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-07-29","conditions":"Colorectal Cancer Metastatic","enrollment":194},{"nctId":"NCT03401294","phase":"PHASE2","title":"Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.","status":"RECRUITING","sponsor":"University of Saskatchewan","startDate":"2025-05-01","conditions":"Metastatic Colorectal Cancer","enrollment":32},{"nctId":"NCT05375708","phase":"PHASE2","title":"Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites","status":"SUSPENDED","sponsor":"UMC Utrecht","startDate":"2025-12-01","conditions":"Metastatic Colorectal Cancer, Oligometastatic Disease","enrollment":93},{"nctId":"NCT04072198","phase":"PHASE2","title":"Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients","status":"COMPLETED","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2019-09-26","conditions":"Colorectal Cancer","enrollment":73},{"nctId":"NCT06857773","phase":"PHASE3","title":"Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-11-21","conditions":"Colorectal Neoplasms, Floxuridine, Liver Metastases","enrollment":306},{"nctId":"NCT02162563","phase":"PHASE3","title":"Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2014-07","conditions":"Colorectal Cancer, Liver Metastases","enrollment":530},{"nctId":"NCT03117972","phase":"PHASE2","title":"Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2017-08-04","conditions":"Metastatic Colorectal Cancer","enrollment":54},{"nctId":"NCT04607668","phase":"PHASE3","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-01-06","conditions":"Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity","enrollment":326},{"nctId":"NCT06575127","phase":"PHASE2","title":"Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study","status":"RECRUITING","sponsor":"Al-Azhar University","startDate":"2024-08-17","conditions":"Neoplasm Malignant, Colon Cancer Stage 4","enrollment":60},{"nctId":"NCT02842580","phase":"PHASE2","title":"De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-09","conditions":"Colorectal Neoplasms","enrollment":21},{"nctId":"NCT05839470","phase":"PHASE2","title":"Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-11-19","conditions":"Colorectal Cancer","enrollment":20},{"nctId":"NCT04034459","phase":"PHASE2","title":"FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2016-11-25","conditions":"Metastatic Colorectal Cancer","enrollment":109},{"nctId":"NCT05862051","phase":"NA","title":"RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-14","conditions":"Colorectal Cancer, Oligometastatic Disease","enrollment":75},{"nctId":"NCT03721653","phase":"PHASE2","title":"FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2018-11-30","conditions":"Metastatic Colorectal Cancer","enrollment":218},{"nctId":"NCT05354674","phase":"","title":"Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2023-09-01","conditions":"Colorectal Cancer, Liver Metastases","enrollment":302},{"nctId":"NCT03251612","phase":"PHASE2","title":"Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2017-09-22","conditions":"Colorectal Cancer Metastatic","enrollment":90},{"nctId":"NCT05353582","phase":"PHASE2","title":"Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-06-01","conditions":"Colorectal Neoplasms, Colorectal Cancer, Colorectal Cancer Metastatic","enrollment":168},{"nctId":"NCT04852250","phase":"","title":"Centralized Tumour Board and Secondary Intervention Rate in mCRC","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2021-06-01","conditions":"Metastatic Colorectal Cancer, RAS Mutation, Multidisciplinary Communication","enrollment":130},{"nctId":"NCT04832776","phase":"PHASE2","title":"FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-04-17","conditions":"Liver Metastasis Colon Cancer","enrollment":160},{"nctId":"NCT02015923","phase":"PHASE4","title":"Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2013-12","conditions":"Colonic Cancer, Unresectable Metastasis Originating in Colonic Cancer","enrollment":107},{"nctId":"NCT03641976","phase":"PHASE2","title":"A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-01-03","conditions":"Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy, Unresectable Metastatic Right-sided Colon Cancer, Stage IV","enrollment":120},{"nctId":"NCT02497157","phase":"PHASE2","title":"Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2015-05-21","conditions":"Metastatic Colorectal Cancer","enrollment":45},{"nctId":"NCT02339116","phase":"PHASE3","title":"Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC","status":"UNKNOWN","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2015-02-26","conditions":"Metastatic Colorectal Cancer","enrollment":654},{"nctId":"NCT04097444","phase":"PHASE2","title":"CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC","status":"UNKNOWN","sponsor":"Chugai Pharmaceutical","startDate":"2019-10-11","conditions":"Metastatic Colorectal Cancer","enrollment":112},{"nctId":"NCT01650428","phase":"PHASE2","title":"Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-04","conditions":"Rectal Cancer","enrollment":20},{"nctId":"NCT01802645","phase":"PHASE2","title":"Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2013-03","conditions":"Colorectal Cancer","enrollment":91},{"nctId":"NCT01640405","phase":"PHASE3","title":"Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2012-07","conditions":"Metastatic Colorectal Cancer","enrollment":350},{"nctId":"NCT03711240","phase":"PHASE2","title":"The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2019-01-08","conditions":"Colorectal Cancer","enrollment":40},{"nctId":"NCT03085992","phase":"PHASE2","title":"Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer","status":"COMPLETED","sponsor":"Azienda Ospedaliero, Universitaria Pisana","startDate":"2012-03","conditions":"Rectal Cancer","enrollment":49},{"nctId":"NCT02271464","phase":"PHASE2","title":"Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Azienda Ospedaliero, Universitaria Pisana","startDate":"2012-03","conditions":"Metastatic Colorectal Cancer","enrollment":232},{"nctId":"NCT01765582","phase":"PHASE2","title":"Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2013-01-23","conditions":"Colorectal Neoplasms","enrollment":280},{"nctId":"NCT02175654","phase":"PHASE2","title":"Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab","status":"TERMINATED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2014-06","conditions":"Colorectal Neoplasms, Metastatic Disease","enrollment":15},{"nctId":"NCT02246049","phase":"PHASE2","title":"A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC","status":"COMPLETED","sponsor":"EPS Corporation","startDate":"2014-05","conditions":"Colorectal Neoplasms","enrollment":69},{"nctId":"NCT00778102","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-10","conditions":"Colorectal Cancer","enrollment":80},{"nctId":"NCT00940303","phase":"PHASE2","title":"OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-06","conditions":"Colorectal Cancer","enrollment":97},{"nctId":"NCT02350530","phase":"PHASE2","title":"FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-01","conditions":"Metastatic Colorectal Cancer","enrollment":138},{"nctId":"NCT02591667","phase":"PHASE2","title":"Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2016-03","conditions":"Colorectal Cancer, Peritoneal Metastasis","enrollment":30},{"nctId":"NCT02515734","phase":"PHASE2","title":"A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab","status":"UNKNOWN","sponsor":"Japan Clinical Cancer Research Organization","startDate":"2015-08","conditions":"Colorectal Cancer","enrollment":360},{"nctId":"NCT02295930","phase":"PHASE2","title":"Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2011-10","conditions":"Metastatic Colorectal Cancer","enrollment":143},{"nctId":"NCT00719797","phase":"PHASE3","title":"Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2008-07","conditions":"Colorectal Cancer","enrollment":509},{"nctId":"NCT01163396","phase":"PHASE2","title":"First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2007-07","conditions":"Colorectal Cancer Metastatic","enrollment":57},{"nctId":"NCT01540435","phase":"PHASE2","title":"Perioperative Treatment of Resectable Liver Metastases","status":"WITHDRAWN","sponsor":"University of Regensburg","startDate":"2012-09","conditions":"Colon Cancer Liver Metastasis","enrollment":""},{"nctId":"NCT01437618","phase":"","title":"First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Azienda Ospedaliero, Universitaria Pisana","startDate":"2009-06","conditions":"Metastatic Colorectal Cancer","enrollment":15},{"nctId":"NCT01126866","phase":"PHASE2","title":"Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy","status":"TERMINATED","sponsor":"National Center for Tumor Diseases, Heidelberg","startDate":"2009-06","conditions":"Colorectal Carcinoma","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bevacizumab","Irinotecan","Oxaliplatin","5-Fluorouracil"],"phase":"phase_3","status":"active","brandName":"FOLFOXIRI + Bevacizumab","genericName":"FOLFOXIRI + Bevacizumab","companyName":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","companyId":"spanish-cooperative-group-for-the-treatment-of-digestive-tumours-ttd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFOXIRI is a combination chemotherapy regimen that inhibits DNA synthesis and cell division, while bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor (VEGF). Used for Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}